RALEIGH, N.C.--(BUSINESS WIRE)--Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN ® ...

RESEARCH TRIANGLE PARK – Raleigh-based Merz North America has received approval from the U.S. Food and Drug Administration to market a treatment for blepharospasm, or involuntary blinking, in adults.

Physicists at the University of California, San Diego have discovered a neural circuit in rats that could provide a powerful model for understanding a neurological condition known as ...